Fractyl Health, Inc. GUTS
0.88 USD +0.07 (+8.70%)
At closeNov 12, 2026, 4:06 AM EST
0.88 0.00 0.00%
Pre-market · Nov 12, 4:06 AM ET
0.8001 Day range 0.891
0.8001 52-week range 29.34
- YTD
- -96.66%
- 1 year
- -93.32%
News
defenseworld.net Fractyl Health, Inc. (NASDAQ:GUTS) Stock Has Consensus Price Target of $50.25 According to Brokerages Shares of Fractyl Health, Inc. (NASDAQ: GUTS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five brokerages that are presently covering the company, Marketbeat…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
globenewswire.com Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026 BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel…
benzinga.com Fractyl Health Expands Revita Patent Portfolio Ahead Of Planned FDA De Novo Submission Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today…
benzinga.com Fractyl Health Announces Heightened Focus On Advancing Revita Toward Potential FDA Marketing Authorization And Commercialization In Post-GLP-1 Weight Maintenance Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027Workforce…- benzinga.com Canaccord Genuity Maintains Buy on Fractyl Health, Lowers Price Target to $39 Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and lowers the price target from $96 to $39.
benzinga.com Morgan Stanley Maintains Equal-Weight on Fractyl Health, Lowers Price Target to $4 Morgan Stanley analyst Michael Ulz maintains Fractyl Health (NASDAQ:GUTS) with a Equal-Weight and lowers the price target from $24 to $4.
benzinga.com Crude Oil Jumps 3%; Citizens Financial Earnings Top Views U.S. stocks fell Friday, led by Nasdaq’s 1.86% drop; energy rose, communication services sank. Oil topped $100 as CFG beat earnings estimates.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Marker Therapeutics (NASDAQ:MRKR) stock increased by 21.2% to $1.11 during Friday's regular session. The market value of their outstanding shares is at $14.8 million. Alaunos Therapeutics…
benzinga.com Why Fractyl Health Stock Is Sinking Friday Fractyl Health (GUTS) stock sank 50% despite positive REMAIN-1 trial results as class action lawsuit concerns weigh on investors.
benzinga.com Dow Surges 250 Points; M&T Bank Posts Upbeat Q3 Earnings U.S. stocks mixed: Dow +0.48%, Nasdaq -0.65%, S&P -0.05%. Energy rose, tech fell, and M&T Bank beat Q3 estimates; oil eased, gold gained.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares increased by 27.9% to $2.79 during Friday's pre-market session. The company's market cap stands at $5.2 million. Picard Medical (AMEX:PMI) stock…
- benzinga.com Fractyl Health’s REMAIN-1 Study Meets Six-Month Co-Primary Endpoint With High Statistical Significance; Demonstrates 80% Retention Of GLP-1 Induced Weight Loss Vs 67% For Sham REMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023; mITT population); demonstrated 80% retention of GLP-1 induced weight loss vs 67% for sham32% of Revita®…